Yes, not a bad deal. With only one drug, competing with multiple biosimilars in rapidly shrinking long acting G-CSF market, Spectrum would have a bleak future. After Poziotinib rejection, buyout or merger were right things to do.
I am reading more about Indocin. Not sure I like this quote, "In 2008, a box of 30 anti-inflammatory rectal suppositories that treats arthritis, called Indocin, had a price tag of $198. As of Oct. 1, 2021, the price of that same box was 52 times higher, totaling $10,350".
News 
Market Data 
Discover 
